CAMBRIDGE, Mass., June 1, 2016 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a leader in discovering and developing
highly selective kinase medicines for patients with genomically
defined diseases, today announced its participation in the
following upcoming investor conferences:
- Goldman Sachs 37th Annual Global Healthcare
Conference in Rancho Palos Verdes,
CA on Wednesday, June 8, 2016
at 3:20 p.m. PT (6:20 p.m. ET).
- JMP Securities Life Sciences Conference in New York, NY on Tuesday, June 21, 2016 at 9:30 a.m. ET.
A live webcast of each presentation will be available by
visiting the Investors section of Blueprint Medicines' website at
http://ir.blueprintmedicines.com. A replay of the webcast will be
archived on Blueprint Medicines' website for 30 days following each
presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
highly selective and potent kinase medicines to improve the lives
of patients with genomically defined diseases. The Company's
approach is rooted in a deep understanding of the genetic blueprint
of cancer and other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing three programs
in clinical development for subsets of patients with
gastrointestinal stromal tumors, hepatocellular carcinoma and
systemic mastocytosis, as well as multiple programs in research and
preclinical development. For more information, please
visit www.blueprintmedicines.com.
Logo -
http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-june-300278146.html
SOURCE Blueprint Medicines Corporation